Inhibitor Therapeutics Inc (INTI):企業の財務・戦略的SWOT分析

◆英語タイトル:Inhibitor Therapeutics Inc (INTI) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH496811FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Inhibitor Therapeutics Inc (INTI) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Inhibitor Therapeutics Inc (Inhibitor) formerly known as Hedgepath Pharmaceuticals Inc, a subsidiary of Mayne Pharma Group Ltd, is a clinical stage biopharmaceutical company that discovers, develops and commercializes novel therapeutics for the treatment of prostrate, and lung cancers. The company is investigating an oral formulation of Itraconazole in phase 2b clinical trials for the treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome. It employs super bioavailability technology (SUBA), a novel drug delivery technology that improves the bioavailability of orally administered drugs which have limited solubility. The company holds an exclusive licensee for Mayne Pharma Group’s SUBA-Itraconazole. Inhibitor is headquartered in Tampa, Florida, the US.

Inhibitor Therapeutics Inc Key Recent Developments

May 03,2020: Inhibitor Therapeutics receives loan under Paycheck Protection Program

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Inhibitor Therapeutics Inc – Key Facts
Inhibitor Therapeutics Inc – Key Employees
Inhibitor Therapeutics Inc – Key Employee Biographies
Inhibitor Therapeutics Inc – Major Products and Services
Inhibitor Therapeutics Inc – History
Inhibitor Therapeutics Inc – Company Statement
Inhibitor Therapeutics Inc – Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Company Overview
Inhibitor Therapeutics Inc – Business Description
R&D Overview
Inhibitor Therapeutics Inc – Corporate Strategy
Inhibitor Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Inhibitor Therapeutics Inc – Strengths
Inhibitor Therapeutics Inc – Weaknesses
Inhibitor Therapeutics Inc – Opportunities
Inhibitor Therapeutics Inc – Threats
Inhibitor Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 03, 2020: Inhibitor Therapeutics receives loan under Paycheck Protection Program
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Inhibitor Therapeutics Inc, Key Facts
Inhibitor Therapeutics Inc, Key Employees
Inhibitor Therapeutics Inc, Key Employee Biographies
Inhibitor Therapeutics Inc, Major Products and Services
Inhibitor Therapeutics Inc, History
Inhibitor Therapeutics Inc, Key Competitors
Inhibitor Therapeutics Inc, Ratios based on current share price
Inhibitor Therapeutics Inc, Annual Ratios
Inhibitor Therapeutics Inc, Annual Ratios (Cont...1)
Inhibitor Therapeutics Inc, Interim Ratios
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Inhibitor Therapeutics Inc (INTI):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Miyazaki Bank Ltd.:企業の戦略・SWOT・財務情報
    The Miyazaki Bank Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Miyazaki Bank Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Hitachi, Ltd.:企業のM&A・事業提携・投資動向
    Hitachi, Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hitachi, Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Ternium SA:戦略・SWOT・企業財務分析
    Ternium SA - Strategy, SWOT and Corporate Finance Report Summary Ternium SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • TISCO Financial Group PCL:企業の戦略・SWOT・財務分析
    TISCO Financial Group PCL - Strategy, SWOT and Corporate Finance Report Summary TISCO Financial Group PCL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • PromptCare Inc-医療機器分野:企業M&A・提携分析
    Summary PromptCare Inc (PromptCare) is a healthcare center that respiratory products and home infusion services. The center provides respiratory services such as clinical support programs, patient-focused technology and testimonials. It provides home infusion therapies for patients of all ages with …
  • University of Southampton:製薬・医療:M&Aディール及び事業提携情報
    Summary University of Southampton (UOS) is an educational institution that offers education and research services. The institute provides educational programs in the fields of accounting and finance, acoustical engineering, aeronautics and astronautics, anthropology, archaeology, biochemistry, biolo …
  • CytImmune Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CytImmune Sciences Inc (CytImmune) is a clinical stage nanomedicine company that discovers, develops, and commercializes tumor-targeted therapies. The company develops nanotherapy platform, Aurimune, a tumor-targeted trojan horse. Its Aurimune binds TNF receptors on blood vessel cells at the …
  • Sime Darby Berhad:企業の戦略・SWOT・財務分析
    Sime Darby Berhad - Strategy, SWOT and Corporate Finance Report Summary Sime Darby Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Resonance Health Ltd (RHT):企業の財務・戦略的SWOT分析
    Summary Resonance Health Ltd (Resonance Health) is a healthcare solution provider that offers non-invasive medical imaging software and services. The company offers FerriScan analysis software for the measurement of liver iron concentration (LIC); FerriScan with Cardiac T2* dual analysis service to …
  • United Parcel Service Inc (UPS):企業の財務・戦略的SWOT分析
    United Parcel Service Inc (UPS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Tosoh Corporation:企業の戦略・SWOT・財務分析
    Tosoh Corporation - Strategy, SWOT and Corporate Finance Report Summary Tosoh Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • PetroQuest Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    PetroQuest Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary PetroQuest Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive inform …
  • City Utilities of Springfield:発電所・企業SWOT分析
    City Utilities of Springfield - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Matrai Eromu ZRt:企業の戦略的SWOT分析
    Matrai Eromu ZRt - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Coca-Cola HBC AG:企業の戦略・SWOT・財務情報
    Coca-Cola HBC AG - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola HBC AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • NWS Holdings Limited:企業の戦略・SWOT・財務情報
    NWS Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary NWS Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Getinge AB (GETI B):企業の財務・戦略的SWOT分析
    Getinge AB (GETI B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Allied World Assurance Company Holdings, GmbH:企業の戦略・SWOT・財務情報
    Allied World Assurance Company Holdings, GmbH - Strategy, SWOT and Corporate Finance Report Summary Allied World Assurance Company Holdings, GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • Saladax Biomedical Inc:企業の製品パイプライン分析2018
    Summary Saladax Biomedical Inc (Saladax) is a medical equipment company that develops diagnostic tests. The company provides products such as My5-FU, MyPaclitaxel, MyImatinib and MyDocetaxel, among others. Its My5-FU measures and helps physicians to optimize a patient’s exposure to 5-fluorouracil, M …
  • JFE Holdings, Inc.:戦略・SWOT・企業財務分析
    JFE Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary JFE Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆